Evidence map›Paper›PMID 24026889›Full record

ArticleDer Urologe. Ausg. A2013

[Infection and sepsis prevention in prostate biopsy].

F M E Wagenlehner, A Pilatz, P Waliszewski, T Dansranjavin, W Weidner

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

F M E WagenlehnerKlinik für Urologie, Kinderurologie und Andrologie, Universitätsklinikum Giessen und Marburg GmbH, Standort Giessen, Justus-Liebig-Universität, Rudolf-Buchheim-Str. 7, 35392, Giessen, Deutschland, Wagenlehner@AOL.com.
A Pilatz
P Waliszewski
T Dansranjavin
W Weidner

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate biopsy is currently the gold standard in the diagnosis of carcinoma of the prostate. An estimated one million prostate biopsies are performed every year in Europe. Worldwide the most frequent form is the transrectal prostate biopsy using preoperative fluoroquinolone prophylaxis. In recent years an increasing rate of infectious complications after prostate biopsy has been observed. The main causative factor is fecal fluoroquinolone-resistant bacteria. This review aims to present the current evidence regarding infectious complications after prostate biopsy and strategies to reduce symptomatic infections and urosepsis.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsBiopsy, NeedleEvidence-Based MedicineHumansMalePremedicationProstatic NeoplasmsSepsisUrinary Tract InfectionsAnti-Bacterial Agents

Identifiers

PMID24026889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.